China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its investigational drug YKYY015, targeting primary hypercholesterolemia or mixed hyperlipidemia characterized by elevated LDL-C levels.
YKYY015, an siRNA drug, is distinctive for its integration with Youcare’s proprietary GalNAc delivery system. Utilizing siRNA interference silencing mechanism, YKYY015 silences PCSK9 mRNA at its source, effectively blocking the synthesis of PCSK9 protein. This reduction in PCSK9 protein binding to LDL-R promotes the recycling of LDL-R, thereby increasing the uptake and degradation of plasma LDL-C. The drug is designed to more effectively clear LDL-C from the blood and reduce the risk of atherosclerosis in patients. YKYY015 is anticipated to achieve sustainable inhibition of PCSK9 protein synthesis in the liver with only two injections per year, effectively reducing plasma LDL-C levels and controlling blood lipids.- Flcube.com
